Dynavax Technologies Corporation (FRA:DYF1)

Germany flag Germany · Delayed Price · Currency is EUR
13.25
+0.08 (0.61%)
At close: Jan 16, 2026
10.14%
Market Cap1.48B -7.1%
Revenue (ttm)281.70M +26.7%
Net Income-36.99M
EPS-0.31
Shares Outn/a
PE Ration/a
Forward PE20.29
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume134
Open13.21
Previous Close13.17
Day's Range13.20 - 13.25
52-Week Range7.65 - 13.57
Betan/a
RSI60.95
Earnings DateFeb 20, 2026

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 405
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol DYF1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements